Evaluation of a commercial real-time PCR kit for the detection of the Q80K polymorphism in plasma from HCV genotype 1a infected patients

Journal of Clinical Virology

Volumn 76, Issue , 2016, Pages 20-23

  Vicenti, Ilaria ^a   Falasca, Francesca ^b   Sticchi, Laura ^c,d   Bruzzone, Bianca ^c   Turriziani, Ombretta ^b   Zazzi, Maurizio ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Drug resistance assay; HCV; Natural polymorphisms; Q80K; Simeprevir

Indexed keywords

NONSTRUCTURAL PROTEIN 3; ANTIVIRUS AGENT; DIAGNOSTIC KIT; NS3 PROTEIN, HEPATITIS C VIRUS; SIMEPREVIR; VIRAL PROTEIN;

ARTICLE; CODON; DNA POLYMORPHISM; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; POLYMERASE CHAIN REACTION SYSTEM; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; WILD TYPE; ANTIVIRAL RESISTANCE; BLOOD; DIAGNOSTIC KIT; EVALUATION STUDY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; ITALY; PROCEDURES; STANDARDS; VIROLOGY;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; ITALY; POLYMORPHISM, GENETIC; REAGENT KITS, DIAGNOSTIC; REAL-TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SIMEPREVIR; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84958161018     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2016.01.006     Document Type: Article

References (20)

1. Gutierrez J.A., Lawitz E.J., Poordad F. Interferon-free, direct-acting antiviral therapy for chronic hepatitis C. J. Viral Hepat. 2015, 22:861-870.
2. AASLD/IDSA HCV Guidance Panel. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus, Hepatology 62 (2015) 932-954.
3. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015, J. Hepatol. 63 (2015) 199-236.
4. Lenz O., Verbinnen T., Lin T.I., Vijgen L., Cummings M.D., Lindberg J., et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob. Agents Chemother. 2010, 54:1878-1887.
5. Jacobson I.M., Dore G.J., Foster G.R., Fried M.W., Radu M., Rafalsky V.V., et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3 randomised, double-blind, placebo-controlled trial. Lancet 2014, 384:403-413.
6. Manns M., Marcellin P., Poordad F., de Araujo E.S., Buti M., Horsmans Y., et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised double-blind, placebo-controlled phase 3 trial. Lancet 2014, 384:414-426.
7. Forns X., Lawitz E., Zeuzem S., Gane E., Bronowicki J.P., Andreone P., et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology 2014, 146:1669-1679.
8. Moreno C., Hezode C., Marcellin P., Bourgeois S., Francque S., Samuel D., et al. Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4. J. Hepatol. 2015, 62:1047-1055.
9. Lenz O., Verbinnen T., Fevery B., Tambuyzer L., Vijgen L., Peeters M., et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in phase IIb/III studies. J. Hepatol. 2015, 62:1008-1014.
10. Sarrazin C., Lathouwers E., Peeters M., Daems B., Buelens A., Witek J., et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antiviral Res. 2015, 116:10-16.
11. Vidal L.L., Santos A.F., Soares M.A. Worldwide distribution of the NS3 gene 80K polymorphism among circulating hepatitis C genotype 1 viruses: implication for simeprevir usage. J. Antimicrob. Chemother. 2015, 70:2024-2027.
12. Hajji H., Aherfi S., Motte A. Diversity of 1,213 hepatitis C virus NS3 protease sequences from a clinical virology laboratory database in Marseille university hospitals, southeastern France. J. Med. Virol. 2015, 87:1921-1933.
13. Pickett B.E., Striker R., Lefkowitz E.J. Evidence for separation of HCV subtype 1a into two distinct clades. J. Viral Hepat. 2011, 18:608-618.
14. Vicenti I., Rosi A., Saladini F., Meini G., Pippi F., Rossetti B., et al. Naturally occurring hepatitis C virus (HCV) NS3/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy. J. Antimicrob. Chemother. 2012, 67:984-987.
15. Chevaliez S., Bouvier-Alias M., Brillet R., Pawlotsky J.M. Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice. PLoS One 2009, 12.
16. McCloskey R.M., Liang R.H., Joy J.B., Krajden M., Montaner J.S., Harrigan P.R., et al. Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism. J. Infect. Dis. 2015, 211:1288-1295.
17. De Luca A., Di Giambenedetto S., Lo Presti A., Sierra S., Prosperi M., Cella E., et al. Two distinct hepatitis C virus genotype 1a clades have different geographical distribution and association with natural resistance to NS3 protease inhibitors. Open Forum Infect. Dis. 2015, 31.
18. Chui C.K., Dong W.W., Joy J.B., Poon A.F., Dong W.Y., Mo T., et al. Development and validation of two screening assays for the HCV NS3 Q80K polymorphism associated with reduced response to combination treatment regimens containing simeprevir. J. Clin. Microbiol. 2015, 53:2942-2950.
19. Lontok E., Harrington P., Howe A., Kieffer T., Lennerstrand J., Lenz O., et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology 2015, 62:1623-1632.
20. Beloukas A., King S., Childs K., Papadimitropoulos A., Hopkins M., Atkins M., et al. Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK. Clin. Microbiol. 2015, 21:1033-1039.